Centro de Investigación de Medicina Aplicada (CIMA)
Centro / Instituto vinculado a la Universidad de Navarra
Hospital Universitario de Valladolid
Valladolid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Valladolid (25)
2024
-
Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)
Gastroenterologia y Hepatologia
-
Status of head and neck brachytherapy in Spain in 2022
Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 456-460
2021
-
Author Correction: The utility of Next Generation Sequencing for molecular diagnostics in Rett syndrome (Scientific Reports, (2017), 7, 1, (12288), 10.1038/s41598-017-11620-3)
Scientific Reports
-
Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
Leukemia, Vol. 35, Núm. 1, pp. 245-249
-
Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 6, pp. 586-598
-
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
Scientific Reports, Vol. 11, Núm. 1
-
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development
Blood, Vol. 138, Núm. 17, pp. 1583-1589
2020
-
Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus (Frontiers in Immunology, (2019), 10, 10.3389/fimmu.2019.01151)
Frontiers in Immunology
-
Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study
Journal of Neuro-Oncology, Vol. 148, Núm. 3, pp. 545-554
2019
-
Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus
Frontiers in Immunology, Vol. 10, Núm. JUN
-
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
Leukemia, Vol. 33, Núm. 5, pp. 1256-1267
-
X chromosome inactivation does not necessarily determine the severity of the phenotype in Rett syndrome patients
Scientific Reports, Vol. 9, Núm. 1
2017
-
The utility of Next Generation Sequencing for molecular diagnostics in Rett syndrome
Scientific Reports, Vol. 7, Núm. 1
2016
-
Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia
Leukemia Research, Vol. 40, pp. 1-9
-
Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis
Blood, Vol. 127, Núm. 24, pp. 3035-3039
2015
-
Common variants of NFE2L2 gene predisposes to acute respiratory distress syndrome in patients with severe sepsis
Critical Care, Vol. 19, Núm. 1
-
PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
Leukemia
-
The cellular origin and malignant transformation of Waldenström macroglobulinemia
Blood, Vol. 125, Núm. 15, pp. 2370-2380
2014
-
Multiparameter flow cytometry for staging of solitary bone plasmacytoma: New criteria for risk of progression to myeloma
Blood, Vol. 124, Núm. 8, pp. 1300-1303
-
Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: New criteria for differential diagnosis and risk stratification
Leukemia, Vol. 28, Núm. 1, pp. 166-173